Biotech · Private company · Chapel Hill, NC, US
NeuroGT
Track this companyFree. Adds NeuroGT to your Dealase workspace and tells you when its record changes.
Clinical trials11 recruiting or active
Pipeline programs1From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline1
- rAAV9-CMV-hNAGLUopPhase 2 · Sanfilippo Syndrome (MPS III)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials1
- Single Injection of rAAV9-CMV-hNAGLUop Gene for Patients With Mucopolysaccharidosis (MPS) IIIBPHASE1_PHASE2 · NOT_YET_RECRUITING · started Jan 18, 2027ClinicalTrials.gov NCT07818759 · fetched Nov 12, 2026
NIH awards9
- Novel AAV gene therapy for treating CNS neuropathy of MPS IIICFiscal year 2026 · $342.7KNIH RePORTER 5R41NS143578-02 · fetched Nov 12, 2026
- Development of gene therapy product for treating MPS IIIBFiscal year 2026 · $1.3MNIH RePORTER 5R44NS135667-03 · fetched Nov 12, 2026
- Trans-BBB AAV9 gene therapy targeting CNS neuropathy of MPS IFiscal year 2026 · $1.5MNIH RePORTER 5R44NS143501-02 · fetched Nov 12, 2026
- Novel AAV gene therapy for treating CNS neuropathy of MPS IIICFiscal year 2025 · $349.9KNIH RePORTER 1R41NS143578-01 · fetched Nov 12, 2026
- Trans-BBB AAV9 gene therapy targeting CNS neuropathy of MPS IFiscal year 2025 · $1.5MNIH RePORTER 1R44NS143501-01 · fetched Nov 12, 2026
- Development of gene therapy product for treating MPS IIIBFiscal year 2025 · $1.3MNIH RePORTER 4R44NS135667-02 · fetched Nov 12, 2026
- Protein depleting pre-existing antibodies for viral gene therapyFiscal year 2025 · $969.8KNIH RePORTER 5R44AI172670-03 · fetched Nov 12, 2026
- Development of gene therapy product for treating MPS IIIBFiscal year 2024 · $456.4KNIH RePORTER 1R44NS135667-01A1 · fetched Nov 12, 2026
- Protein depleting pre-existing antibodies for viral gene therapyFiscal year 2024 · $1MNIH RePORTER 4R44AI172670-02 · fetched Nov 12, 2026